Companies: 10,795·Total market cap: $144.5T
Cytek Biosciences, Inc.

Cytek Biosciences, Inc.

CTKBNASDAQHealthcare● Active
$4.04
$-0.05(-1.29%)
Market Cap$521361538
P/E Ratio
52W High$6.18
52W Low$2.9
SEC Filings

Cytek Biosciences, Inc. (CTKB) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001831915 · CTKB · NASDAQ · as of Jun 8, 2026

Filing snapshot

434
Total Filings
8-K
Latest Form
2026-06-02
Most Recent
2021
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0001831915 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-02-26
Fiscal Year End
Feb 26, 2026
Accession No.
0001628280-26-012352
Primary Document
ctkb-20251231.htm
Source: data.sec.gov · CIK 0001831915 · Accession 0001628280-26-012352

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-07
8-KCurrent Report
8-K
2026-06-02Material Event
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
8-KCurrent Report
8-K
2026-06-02
View
SDSD
SD
2026-06-01
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-18
View
10-QQuarterly Report
10-Q
2026-05-07
View
8-KCurrent Report
8-K
2026-05-07
View
ARSARS
ARS
2026-04-28
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-04-28
View
DEF 14AProxy Statement
DEF 14A
2026-04-28
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-04-09
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-03-26
View
S-8Employee Stock Plan Registration
S-8
2026-02-27
View
10-KAnnual Report
10-K
2026-02-26
View
8-KCurrent Report
8-K
2026-02-26
View
8-KCurrent Report
8-K
2026-01-13
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2025-11-17
View
Showing 1–15 of 158 filingsForm 4 / 144 hidden· 434 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001831915  |  Exchange: NASDAQ · Healthcare

Cytek Biosciences, Inc. (NASDAQ: CTKB) has submitted 434 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2021. As a Healthcare sector company with CIK 0001831915, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Cytek Biosciences, Inc.'s most comprehensive regulatory disclosure. The most recent Cytek Biosciences, Inc. 10-K was filed on 2026-02-26 for fiscal year ending 2026. Historical CTKB 10-K annual reports are available from 2020 through 2026.

Investors researching Cytek Biosciences, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08

Frequently Asked Questions

CTKB SEC Filings · 8 questions

Cytek Biosciences, Inc. (CTKB) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 434 filings and access original documents at no cost. Cytek Biosciences, Inc.'s CIK is 0001831915.

CTKB SEC filingsCytek Biosciences, Inc. SEC documentsfind CTKB 10-K